The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1453
Rescheduling of Hydrocodone Combination Products
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The Drug Enforcement Administration (DEA) has reclassified all hydrocodone combination products as schedule II controlled substances; they were previously classified as schedule III.1 Hydrocodone alone (Zohydro ER) is already a schedule II controlled substance.2

HYDROCODONE — Hydrocodone is a semisynthetic opioid agonist. It is widely prescribed in combination with acetaminophen or ibuprofen for treatment of pain3 and is also available in combination with homatropine, chlorpheniramine, and/or pseudoephedrine for relief of cough and nasal congestion.

THE NEW SCHEDULE — Schedule II controlled substances are those that have an accepted medical use in the US and a high potential for abuse that can result in severe psychological and physical dependence. Drugs classified ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Rescheduling of Hydrocodone Combination Products
Article code: 1453d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian